Home › Hidradenitis Suppurativa › California › Los Angeles
Hidradenitis Suppurativa clinical trials in Los Angeles, CA
3 studies for Hidradenitis Suppurativa are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
RecruitingPhase 3
- USC Keck School of Medicine, Los Angeles
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Oruka Therapeutics Investigative Site, Los Angeles
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US036, Los Angeles
- Investigative Site US095, Los Angeles
- Investigative Site US067, Los Angeles
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Birmingham, AL5 studies
- Dallas, TX5 studies
- Phoenix, AZ5 studies
- New Orleans, LA4 studies
- Santa Clarita, CA4 studies
- Scottsdale, AZ4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.